175 related articles for article (PubMed ID: 28725066)
1. Editorial: Best Practices in Surveillance of Barrett's Esophagus.
Wani S; Gaddam S
Am J Gastroenterol; 2017 Jul; 112(7):1056-1060. PubMed ID: 28725066
[TBL] [Abstract][Full Text] [Related]
2. Persistence of nondysplastic Barrett's esophagus identifies patients at lower risk for esophageal adenocarcinoma: results from a large multicenter cohort.
Gaddam S; Singh M; Balasubramanian G; Thota P; Gupta N; Wani S; Higbee AD; Mathur SC; Horwhat JD; Rastogi A; Young PE; Cash BD; Bansal A; Vargo JJ; Falk GW; Lieberman DA; Sampliner RE; Sharma P
Gastroenterology; 2013 Sep; 145(3):548-53.e1. PubMed ID: 23714382
[TBL] [Abstract][Full Text] [Related]
3. Minichromosomal Maintenance Component Complex 5 (MCM5) as a Marker of Barrett's Esophagus-Related Neoplasia: A Feasibility Study.
Everson M; Magee C; Alzoubaidi D; Brogden S; Graham D; Lovat LB; Novelli M; Haidry R
Dig Dis Sci; 2019 Oct; 64(10):2815-2822. PubMed ID: 30982210
[TBL] [Abstract][Full Text] [Related]
4. Influence of body mass index on the prevalence and progression of dysplasia in Barrett's esophagus: a retrospective analysis (.).
Thota PN; Arora Z; Benjamin T; Pagadala M; Lopez R; Sanaka MR
Scand J Gastroenterol; 2016 Nov; 51(11):1288-93. PubMed ID: 27460942
[TBL] [Abstract][Full Text] [Related]
5. The Annual Risk of Esophageal Adenocarcinoma Does Not Decrease Over Time in Patients With Barrett's Esophagus.
Nguyen T; Thrift AP; Yu X; Duan Z; El-Serag HB
Am J Gastroenterol; 2017 Jul; 112(7):1049-1055. PubMed ID: 28244499
[TBL] [Abstract][Full Text] [Related]
6. Screening and surveillance for Barrett's esophagus: current issues and future directions.
Choi SE; Hur C
Curr Opin Gastroenterol; 2012 Jul; 28(4):377-81. PubMed ID: 22508325
[TBL] [Abstract][Full Text] [Related]
7. Barrett's esophagus surveillance: When, how often, does it work?
Katona BW; Falk GW
Gastrointest Endosc Clin N Am; 2011 Jan; 21(1):9-24. PubMed ID: 21112494
[TBL] [Abstract][Full Text] [Related]
8. Barrett's esophagus: a retrospective analysis of 13 years surveillance.
Switzer-Taylor V; Schlup M; Lübcke R; Livingstone V; Schultz M
J Gastroenterol Hepatol; 2008 Sep; 23(9):1362-7. PubMed ID: 18205769
[TBL] [Abstract][Full Text] [Related]
9. Negative surveillance endoscopy occurs frequently in patients with short-segment non-dysplastic Barrett's esophagus.
Melson J; Desai V; Greenspan M; Yau S; Abdalla M; Dhanekula R; Mobarhan S; Shapiro D; Losurdo J; Jakate S
Dis Esophagus; 2015 Oct; 28(7):660-5. PubMed ID: 24943293
[TBL] [Abstract][Full Text] [Related]
10. Barrett's esophagus and cancer risk: a more realistic estimate.
Rajendra S; Sharma P
Semin Thorac Cardiovasc Surg; 2011; 23(4):261-2. PubMed ID: 22443641
[TBL] [Abstract][Full Text] [Related]
11. Brush cytology vs. endoscopic biopsy for the surveillance of Barrett's esophagus.
Kumaravel A; Lopez R; Brainard J; Falk GW
Endoscopy; 2010 Oct; 42(10):800-5. PubMed ID: 20821361
[TBL] [Abstract][Full Text] [Related]
12. Management of cancer risk in Barrett's esophagus.
Tan A; Macrae F
J Gastroenterol Hepatol; 2011 Oct; 26(10):1485-92. PubMed ID: 21592226
[TBL] [Abstract][Full Text] [Related]
13. Risk of neoplastic progression in Barrett's esophagus diagnosed as indefinite for dysplasia: a nationwide cohort study.
Kestens C; Leenders M; Offerhaus GJ; van Baal JW; Siersema PD
Endoscopy; 2015 May; 47(5):409-14. PubMed ID: 25521571
[TBL] [Abstract][Full Text] [Related]
14. Significantly lower annual rates of neoplastic progression in short- compared to long-segment non-dysplastic Barrett's esophagus: a systematic review and meta-analysis.
Chandrasekar VT; Hamade N; Desai M; Rai T; Gorrepati VS; Jegadeesan R; Sathyamurthy A; Sharma P
Endoscopy; 2019 Jul; 51(7):665-672. PubMed ID: 30939618
[TBL] [Abstract][Full Text] [Related]
15. Improving cost-effectiveness of endoscopic surveillance for Barrett's esophagus by reducing low-value care: a review of economic evaluations.
Vissapragada R; Bulamu NB; Brumfitt C; Karnon J; Yazbeck R; Watson DI
Surg Endosc; 2021 Nov; 35(11):5905-5917. PubMed ID: 34312726
[TBL] [Abstract][Full Text] [Related]
16. Surveillance and follow-up strategies in patients with high-grade dysplasia in Barrett's esophagus: a Dutch population-based study.
Verbeek RE; van Oijen MG; ten Kate FJ; Vleggaar FP; Schipper ME; Casparie MK; van Baal JW; Siersema PD
Am J Gastroenterol; 2012 Apr; 107(4):534-42. PubMed ID: 22270082
[TBL] [Abstract][Full Text] [Related]
17. Predictors of Progression to High-Grade Dysplasia or Adenocarcinoma in Barrett's Esophagus.
Whitson MJ; Falk GW
Gastroenterol Clin North Am; 2015 Jun; 44(2):299-315. PubMed ID: 26021196
[TBL] [Abstract][Full Text] [Related]
18. The controversy regarding ablation for Barrett's esophagus without dysplasia.
Gaddam S; Muthusamy R; Sharma P
Curr Opin Gastroenterol; 2011 Jul; 27(4):368-73. PubMed ID: 21577102
[TBL] [Abstract][Full Text] [Related]
19. Expression profiles of cancer stem cell markers: CD133, CD44, Musashi-1 and EpCAM in the cardiac mucosa-Barrett's esophagus-early esophageal adenocarcinoma-advanced esophageal adenocarcinoma sequence.
Mokrowiecka A; Veits L; Falkeis C; Musial J; Kordek R; Lochowski M; Kozak J; Wierzchniewska-Lawska A; Vieth M; Malecka-Panas E
Pathol Res Pract; 2017 Mar; 213(3):205-209. PubMed ID: 28216140
[TBL] [Abstract][Full Text] [Related]
20. Dysplasia in short-segment Barrett's esophagus: a prospective 3-year follow-up.
Sharma P; Morales TG; Bhattacharyya A; Garewal HS; Sampliner RE
Am J Gastroenterol; 1997 Nov; 92(11):2012-6. PubMed ID: 9362182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
